Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1263
Revised: March 28, 2024
Accepted: April 24, 2024
Published online: June 15, 2024
Processing time: 172 Days and 13.6 Hours
Cognitive dysfunction is the main manifestation of central neuropathy. Although cognitive impairments tend to be overlooked in patients with diabetes mellitus (DM), there is a growing body of evidence linking DM to cognitive dysfunction. Hyperglycemia is closely related to neurological abnormalities, while often dis
To evaluate the concentrations of cerebral neurotransmitters in T2DM patients exhibiting different hemoglobin A1c (HbA1c) levels.
A total of 130 T2DM patients were enrolled at the Department of Endocrinology of Shanghai East Hospital. The participants were divided into four groups according to their HbA1c levels using the interquartile method, namely Q1 (< 7.875%), Q2 (7.875%-9.050%), Q3 (9.050%-11.200%) and Q4 (≥ 11.200%). Clinical data were collected and measured, including age, height, weight, neck/waist/hip circumferences, blood pressure, comorbidities, duration of DM, and biochemical indicators. Meanwhile, neurotransmitters in the left hippocampus and left brainstem area were detected by proton magnetic resonance spectroscopy.
The HbA1c level was significantly associated with urinary microalbumin (mALB), triglyceride, low-density lipo
The cerebral neurotransmitter concentrations in the left brainstem area in patients with T2DM are closely related to glycemic control, which may be the basis for the changes in cognitive function in diabetic patients.
Core Tip: Diabetic neuropathy is one of the most common chronic complications, and its pathogenesis has not been fully clarified until now, especially the central neuropathy. Cognitive dysfunction is the main manifestation of central neuropathy, although cognitive impairments tend to be neglected in diabetes, there is factually increasing evidence linking diabetes mellitus (DM) to cognitive dysfunction. Several studies indicated that the changes in cerebral neurotransmitter levels are associated with a variety of neurological abnormalities. Here, we described the relationship between cerebral neurotransmitters concentrations that were measured using proton magnetic resonance spectroscopy and hemoglobin A1c levels in patients with type 2 DM.